{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:00:08Z","timestamp":1790456408145,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011621","name":"Winship Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA138292"],"award-info":[{"award-number":["P30CA138292"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.clgc.2026.102657","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:23:08Z","timestamp":1788452588000},"page":"102657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Every Other Week Gemcitabine and Docetaxel (GEMDOC) in Heavily Pretreated Metastatic Castration Resistant Prostate Cancer: A Retrospective Real-world Analysis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0524-8035","authenticated-orcid":false,"given":"Jordan","family":"Ciuro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Asim","family":"Bilen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Carthon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Berchuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Kucuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clgc.2026.102657_bib0001","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA"},{"issue":"7","key":"10.1016\/j.clgc.2026.102657_bib0002","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s11864-024-01215-2","article-title":"Metastatic castration-resistant prostate cancer: advances in treatment and symptom management","volume":"25","author":"Kulasegaran","year":"2024","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102657_bib0003","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41391-023-00725-8","article-title":"Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer (mCRPC) in the US Medicare population","volume":"27","author":"Freedland","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2026.102657_bib0004","first-page":"243","article-title":"Metastatic castration-resistant prostate cancer: insights on current therapy and promising experimental drugs","volume":"15","author":"Ferretti","year":"2023","journal-title":"Res Rep Urol"},{"issue":"16_suppl","key":"10.1016\/j.clgc.2026.102657_bib0005","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e17032","article-title":"Real-world treatment landscape in advanced metastatic castration resistant prostate cancer","volume":"42","author":"Sacchi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clgc.2026.102657_bib0006","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(25)00189-5","article-title":"Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial","volume":"26","author":"Fizazi","year":"2025","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.clgc.2026.102657_bib0007","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO-25-00007","article-title":"Systemic therapy in patients with metastatic castration-resistant prostate cancer: ASCO guideline update","volume":"43","author":"Garje","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102657_bib0008","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clgc.2021.08.009","article-title":"Comparative cardiovascular safety of novel hormonal agents in metastatic castration-resistant prostate cancer using real-world data","volume":"20","author":"Hu","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2026.102657_bib0009","first-page":"953","article-title":"Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer","volume":"32","author":"Hervonen","year":"2012","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.clgc.2026.102657_bib0010","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(12)70537-5","article-title":"2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial","volume":"14","author":"Kellokumpu-Lehtinen","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102657_bib0011","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/1097-0142(20000801)89:3<516::AID-CNCR6>3.0.CO;2-9","article-title":"Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor","volume":"89","author":"Hejna","year":"2000","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.clgc.2026.102657_bib0012","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1023\/A:1012247311419","article-title":"Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial","volume":"12","author":"Laufman","year":"2001","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102657_bib0013","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/sj.bjc.6690737","article-title":"Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer","volume":"81","author":"Zoli","year":"1999","journal-title":"Br J Cancer"},{"issue":"15","key":"10.1016\/j.clgc.2026.102657_bib0014","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clgc.2026.102657_bib0015","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2016.05.002","article-title":"Docetaxel activity in the era of life-prolonging hormonal therapies for metastatic castration-resistant prostate cancer","volume":"70","author":"Francini","year":"2016","journal-title":"Eur Urol"},{"issue":"26","key":"10.1016\/j.clgc.2026.102657_bib0016","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus Abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"Wit","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clgc.2026.102657_bib0017","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clgc.2026.102657_bib0018","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/cncr.25457","article-title":"Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial","volume":"117","author":"Garcia","year":"2011","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.clgc.2026.102657_bib0019","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1001\/jamaoncol.2023.4255","article-title":"Biweekly vs triweekly Cabazitaxel in older patients with metastatic castration-resistant prostate cancer: the CABASTY phase 3 randomized clinical trial","volume":"9","author":"Oudard","year":"2023","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.clgc.2026.102657_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0313472","article-title":"Biweekly CAPOX versus triweekly CAPOX in the adjuvant therapy of post-surgery CRC: a randomized controlled trial","volume":"20","author":"Zhang","year":"2025","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.clgc.2026.102657_bib0021","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/hed.23522","article-title":"Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: southwest Oncology Group study S0329","volume":"36","author":"Malhotra","year":"2014","journal-title":"Head Neck"},{"issue":"2","key":"10.1016\/j.clgc.2026.102657_bib0022","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4103\/2231-0770.154195","article-title":"Biweekly gemcitabine and paclitaxel in patients with relapsed or metastatic squamous cell carcinoma of the head and neck","volume":"5","author":"Sukari","year":"2015","journal-title":"Avicenna J Med"},{"issue":"7","key":"10.1016\/j.clgc.2026.102657_bib0023","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1634\/theoncologist.2012-0071","article-title":"A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard)","volume":"17","author":"Hurwitz","year":"2012","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.clgc.2026.102657_bib0024","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s10147-019-01414-0","article-title":"Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety","volume":"24","author":"Tanioka","year":"2019","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102657_bib0025","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s10147-015-0911-7","article-title":"Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study)","volume":"21","author":"Matsuda","year":"2016","journal-title":"Int J Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:27:30Z","timestamp":1790454450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1558767326001576"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102657","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Every Other Week Gemcitabine and Docetaxel (GEMDOC) in Heavily Pretreated Metastatic Castration Resistant Prostate Cancer: A Retrospective Real-world Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102657","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102657"}}